Literature DB >> 63324

Absence of thymus-derived lymphocyte markers in myelogenous leukemia (Ph1+) cell line K-562.

C B Lozzio, B B Lozzio, W K Yang, A T Ichiki, E G Bamberger.   

Abstract

The myelogenous leukemia cell line K-562 with a Ph1+chromosome, derived from a patient with chronic myelogenous leukemia in terminal blastic crisis, is not a bone marrow-derived lymphoblastic cell line, because the cells neither produce immunoglobulins nor possess complement receptors. Since it has been suspected that blasts found in some patients with chronic myelogenous leukemia in blastic crisis might be thymus-derived cells, we have studied several parameters to demonstrate that K-562 cells are not thymus-derived lymphoblasts. The results of this study show: (a) no cross-reactivity of antisera to K-562 cells with normal human thymocytes; (b) lack of cytotoxicity of a specific horse anti-human thymocyte globulin for K-562 cells; (c) failure of the treatment of K-562 cells with bovine thymosin to induce antigenic determinant and erythrocyte rosette receptors on K-562 cells; (d) presence of receptors for the Fc portion of immunoglobulin G; (e) absence of terminal deoxynucleotidyl transferase; and (f) cytotoxicity of monkey antiserum to K-562 cells for malignant thymus-derived cells (Molt-4). However, absorption with Molt-4 cells abolished the cross-reactivity with Molt-4 cells, whereas 60% of the antibody to K-562 cells remained in the immune serum. Studies of DNA polymerase activities revealed that K-562 cells have levels of polymerase alpha and beta, like other proliferating cells, and an RNA-dependent DNA polymerase activity, presumably representing polymerase gamma.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 63324

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Characterization of the Fc(IgG) receptor on the pluripotential leukaemia cell K-562.

Authors:  A T Ichiki; C J Wust; C B Lozzio
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

2.  Relationship between the Fc receptor for IgG and the specific associated antigen of the pluripotential leukaemia cell line, K-562.

Authors:  A T Ichiki; B B Lozzio; C J Wust; C B Lozzio
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

3.  Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents.

Authors:  E Huberman; M F Callaham
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

4.  Constitutive nuclear NF-kappa B in cells of the monocyte lineage.

Authors:  M Frankenberger; A Pforte; T Sternsdorf; B Passlick; P A Baeuerle; H W Ziegler-Heitbrock
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

5.  Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.

Authors:  Y Fujimiya; W C Chang; A Bakke; D Horwitz; P K Pattengale
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen.

Authors:  H W Ziegler-Heitbrock; A Fütterer; H Rumpold; D Kraft; R Munker; G Riethmüller
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

7.  A transcriptional enhancer with specificity for erythroid cells is located in the long terminal repeat of the Friend murine leukemia virus.

Authors:  Z Bösze; H J Thiesen; P Charnay
Journal:  EMBO J       Date:  1986-07       Impact factor: 11.598

8.  Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease.

Authors:  D White; D B Jones; T Cooke; N Kirkham
Journal:  Br J Cancer       Date:  1982-10       Impact factor: 7.640

9.  Treatment of fresh human leukaemia cells with actinomycin D enhances their lysability by natural killer cells.

Authors:  H W Ziegler-Heitbrock; J Erhardt; G Riethmüller
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.